Uncategorized
Rhopressa maintains lower IOP through 12 months in Rocket 2 registration trial
Rhopressa maintained IOP lowering in patients with glaucoma or ocular hypertension through 12 months in the Rocket 2 phase 3 registration trial, Aerie Pharmaceuticals announced in a press release. Rocket 2 is the second phase 3 registration trial for Rhopressa (netarsudil ophthalmic solution 0.02%). Aerie previously reported that once-daily Rhopressa had achieved its primary 90-day efficacy endpoint of demonstrating non-inferiority in lowering IOP compared with twice-daily timolol.